Jason Cavalier - 13 Sep 2021 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Financial Officer
Signature
/s/ Jason Cavalier
Issuer symbol
LYRA
Transactions as of
13 Sep 2021
Net transactions value
$0
Form type
4
Filing time
15 Sep 2021, 17:44:07 UTC
Next filing
15 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Options (Right to Buy) Award $0 +104,000 $0.000000 104,000 13 Sep 2021 Common Stock 104,000 $8.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable as to 25% of the underlying shares on September 13, 2022 and in 36 substantially equal monthly installments thereafter.